English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose  We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O 6 -BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O 6 -BG. In addition, plasma concentrations of O 6 -BG and O 6 -benzyl-8-oxoguanine were evaluated after O 6 -BG.    Patients and Methods  For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O 6 -BG infusion at 120 mg/m 2 followed by a continuous infusion at an initial dose of 30 mg/m 2 /d for 48 hours. The dose of the continuous infusion of O 6 -BG escalated until tumor AGT was depleted. Once the O 6 -BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O 6 -BG infusion, was escalated until the MTD was determined.    Results  The O 6 -BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m 2 over 1 hour followed by a continuous infusion of 30 mg/m 2 /d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m 2 with dose-limiting toxicities limited to myelosuppression.    Conclusion  This study provides the foundation for a phase II trial of O 6 -BG plus temozolomide in temozolomide-resistant MG.

Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Phase I Trial of Temozolomide Plus O⁶-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma